CR6656A - Forma de dosificacion de farmacos accionada por un hidrogel - Google Patents

Forma de dosificacion de farmacos accionada por un hidrogel

Info

Publication number
CR6656A
CR6656A CR6656A CR6656A CR6656A CR 6656 A CR6656 A CR 6656A CR 6656 A CR6656 A CR 6656A CR 6656 A CR6656 A CR 6656A CR 6656 A CR6656 A CR 6656A
Authority
CR
Costa Rica
Prior art keywords
drug
core
dosage form
water
hydrogel
Prior art date
Application number
CR6656A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
Arthur Beyerinck Ronald
Brian Childlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Lincoln Smith Kelly
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR6656A publication Critical patent/CR6656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Una forma de dosificacion de liberacion controlada tiene un nucleo recubierto, comprendiendo el nucleo una composicion que contiene a un farmaco y una composicion hinchable en agua, ocupando cada una regiones separadas en el nucleo. La composicion que contiene el farmaco comprende un farmaco de solubilidad baja y un agente que retiene el farmaco. El recubrimiento alrededor del nucleo es permeable al agua e insoluble en agua y tiene por lo menos un orificio de salida. Se describen diversas formulaciones que tienen perfiles especificos de liberacion del farmaco.
CR6656A 1999-12-23 2002-06-04 Forma de dosificacion de farmacos accionada por un hidrogel CR6656A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17196899P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
CR6656A true CR6656A (es) 2004-04-29

Family

ID=22625827

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6656A CR6656A (es) 1999-12-23 2002-06-04 Forma de dosificacion de farmacos accionada por un hidrogel

Country Status (42)

Country Link
US (3) US20020015731A1 (es)
EP (2) EP1242055B1 (es)
JP (1) JP4100910B2 (es)
KR (1) KR100523127B1 (es)
CN (1) CN1402632A (es)
AP (1) AP2002002553A0 (es)
AR (1) AR027091A1 (es)
AT (1) ATE392890T1 (es)
AU (1) AU783685B2 (es)
BG (1) BG106865A (es)
BR (1) BR0016708A (es)
CA (1) CA2395333C (es)
CR (1) CR6656A (es)
CZ (1) CZ20022046A3 (es)
DE (1) DE60038698T2 (es)
DK (1) DK1242055T3 (es)
DZ (1) DZ3228A1 (es)
EA (1) EA004370B1 (es)
EE (1) EE200200361A (es)
ES (1) ES2302705T3 (es)
GE (1) GEP20043334B (es)
GT (1) GT200000222A (es)
HU (1) HUP0301242A3 (es)
IL (1) IL149224A0 (es)
IS (1) IS6340A (es)
MA (1) MA26859A1 (es)
MX (1) MXPA02006328A (es)
NO (1) NO20022970L (es)
NZ (1) NZ518281A (es)
OA (1) OA12128A (es)
PA (1) PA8509001A1 (es)
PE (1) PE20010985A1 (es)
PL (1) PL357535A1 (es)
PT (1) PT1242055E (es)
SI (1) SI1242055T1 (es)
SK (1) SK8572002A3 (es)
SV (1) SV2002000250A (es)
TN (1) TNSN00253A1 (es)
TR (1) TR200201646T2 (es)
WO (1) WO2001047500A1 (es)
YU (1) YU35302A (es)
ZA (1) ZA200204960B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1596837A2 (en) * 2003-02-07 2005-11-23 Omega Farma Ehf Sustained release formulations of venlafaxine
EP1622591A1 (en) * 2003-05-06 2006-02-08 Ranbaxy Laboratories, Ltd. Biphasic release of glipizide from monocompartment osmotic dosage form
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
US8715724B2 (en) * 2004-10-29 2014-05-06 Mayne Pharma International Pty Ltd Tabletting process
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
GB0504547D0 (en) * 2005-03-04 2005-04-13 Delsol Products Ltd Personal lubricant
JP5020931B2 (ja) * 2005-03-14 2012-09-05 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 経口薬剤送達システム
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
WO2007057762A2 (en) * 2005-11-16 2007-05-24 Pfizer Limited Osmotic bi-layer tablet
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
CN101439026B (zh) * 2007-11-23 2011-04-06 北京红林制药有限公司 含有多沙唑嗪或其盐的控释制剂及其制备方法
JP2011512349A (ja) * 2008-02-15 2011-04-21 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド 経口放出制御錠剤
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101284368B1 (ko) 2010-07-09 2013-07-15 서울대학교산학협력단 나노섬유시트 기재의 경구용 약물의 제어 전달을 위한 시스템
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
HUE045625T2 (hu) * 2013-01-30 2019-12-30 Daewoong Co Ltd Gyógyászati kompozíciók sebek védelmére, vérpangás szolgáltatására, vagy összetapadás megakadályozására a gyomor- és bél traktusban
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
KR20230038183A (ko) * 2020-07-10 2023-03-17 아데어 파마슈티컬스 인코포레이티드 팽윤성 경구 제약 조성물
BR112023004824A2 (pt) 2020-09-18 2023-04-18 Bristol Myers Squibb Co Formas de dosagem para inibidores tyk2 compreendendo núcleos intumescíveis
WO2023063381A1 (ja) * 2021-10-14 2023-04-20 静岡県公立大学法人 粉末製剤
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IT1165797B (it) * 1982-10-18 1987-04-29 Consiglio Nazionale Ricerche Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5151450A (en) * 1990-02-22 1992-09-29 Tokyo Tanabe Company, Limited Antiulcer substance
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
JP2701977B2 (ja) * 1990-09-28 1998-01-21 ファイザー インク 疎水性媒体を含有する投薬体
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
NZ244682A (en) * 1991-10-10 1993-12-23 Alza Corp Osmotically driven controlled delivery device characterised in that a
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US6436441B1 (en) * 1992-09-18 2002-08-20 Yamanouchi Pharmaceutical Co., Ltd. Hydrogel-forming sustained-release preparation
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5607696A (en) * 1995-02-10 1997-03-04 Alza Corporation Osmotic membrane and delivery device
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
FR2744733B1 (fr) * 1996-02-08 1998-04-24 Ascometal Sa Acier pour la fabrication de piece forgee et procede de fabrication d'une piece forgee
IT1290764B1 (it) * 1996-05-03 1998-12-10 Vevy Europ S P A Pentapeptide per la preparazione di composizioni dermo- farmaceutiche e cosmetiche per il trattamento di lesioni od affezioni cutanee
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6245200B1 (en) 1999-12-10 2001-06-12 Sandia Corporation Photo-oxidation method using MoS2 nanocluster materials
MXPA02006335A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form

Also Published As

Publication number Publication date
TR200201646T2 (tr) 2002-11-21
US20020015731A1 (en) 2002-02-07
GEP20043334B (en) 2004-03-10
DZ3228A1 (fr) 2001-07-05
EA200200595A1 (ru) 2002-12-26
WO2001047500A1 (en) 2001-07-05
DE60038698T2 (de) 2009-05-07
MA26859A1 (fr) 2004-12-20
AR027091A1 (es) 2003-03-12
OA12128A (en) 2006-05-05
AU2018901A (en) 2001-07-09
DK1242055T3 (da) 2008-07-21
SV2002000250A (es) 2002-02-05
US20110182947A1 (en) 2011-07-28
IL149224A0 (en) 2002-11-10
DE60038698D1 (de) 2008-06-05
NZ518281A (en) 2005-01-28
CA2395333C (en) 2009-01-13
EP1242055B1 (en) 2008-04-23
KR20020070330A (ko) 2002-09-05
CA2395333A1 (en) 2001-07-05
CZ20022046A3 (cs) 2002-11-13
US9028870B2 (en) 2015-05-12
PE20010985A1 (es) 2001-09-28
SI1242055T1 (sl) 2008-08-31
TNSN00253A1 (fr) 2002-05-30
HUP0301242A2 (hu) 2004-05-28
KR100523127B1 (ko) 2005-10-20
NO20022970D0 (no) 2002-06-20
BG106865A (bg) 2003-03-31
SK8572002A3 (en) 2002-12-03
PL357535A1 (en) 2004-07-26
PT1242055E (pt) 2008-07-02
CN1402632A (zh) 2003-03-12
US20070087057A1 (en) 2007-04-19
JP2003518489A (ja) 2003-06-10
EE200200361A (et) 2003-10-15
ES2302705T3 (es) 2008-08-01
EA004370B1 (ru) 2004-04-29
NO20022970L (no) 2002-06-20
AU783685B2 (en) 2005-11-24
PA8509001A1 (es) 2002-02-21
YU35302A (sh) 2005-03-15
ZA200204960B (en) 2003-10-02
ATE392890T1 (de) 2008-05-15
HUP0301242A3 (en) 2006-07-28
JP4100910B2 (ja) 2008-06-11
BR0016708A (pt) 2002-10-08
GT200000222A (es) 2002-06-14
EP1967185A1 (en) 2008-09-10
IS6340A (is) 2002-04-12
EP1242055A1 (en) 2002-09-25
MXPA02006328A (es) 2002-12-13
AP2002002553A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ECSP034455A (es) Forma de dosificacion de farmaco activada por hidrogel
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ECSP044974A (es) Formulación de suspensión oral estabilizada
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
UY25544A1 (es) Forma de dosificación de nefazodona
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
SE0001916D0 (sv) Novel formulation
AR020205A1 (es) Formulacion efervescente esterilizante.
GT200600353A (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph.
ECSP003856A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel